Assembly Biosciences Inc. (ASMB)
Assembly Biosciences Inc. (ASMB) Stock Price, Analysis & Data
| Bid | 23.36 |
| Market Cap | 654.19M |
| Revenue (ttm) | 74.84M |
| Net Income (ttm) | -42K |
| Beta | 1.09 |
| EPS (ttm) | 1.24 |
| PE Ratio (ttm) | 25.91 |
| Forward PE | -17.05 |
| P/B (ttm) | 2.09 |
| P/S (ttm) | 8.74 |
| Earnings Date | n/a |
| Ask | 39.68 |
| Volume | 482,051 |
| Avg. Volume (20D) | 228,235 |
| Open | 30.00 |
| Previous Close | 30.01 |
| Day's Range | 30.00 - 33.08 |
| 52-Week Range | 20.23 - 39.71 |
| Analyst | Strong Buy |
| Price Target | 47.5 (47.84%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ASMB
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepa...
Financial Performance
In 2025, Assembly Biosciences's revenue was 72.3M, an increase of 153.52% compared to the previous year's 28.52M. Earnings were -6.12M, a decrease of -84.76%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for ASMB stock is "Strong Buy". The 12-month stock price forecast is 47.5, which is upside of 47.84% from the latest price.
Stock Forecasts
